Strides Pharma Science appoints Dr. C. Muthulingam as Executive VP - R&D
Dr. Muthu was last associated with Mankind Pharma
Dr. Muthu was last associated with Mankind Pharma
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Subscribe To Our Newsletter & Stay Updated